[go: up one dir, main page]

MX2013005954A - Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico. - Google Patents

Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico.

Info

Publication number
MX2013005954A
MX2013005954A MX2013005954A MX2013005954A MX2013005954A MX 2013005954 A MX2013005954 A MX 2013005954A MX 2013005954 A MX2013005954 A MX 2013005954A MX 2013005954 A MX2013005954 A MX 2013005954A MX 2013005954 A MX2013005954 A MX 2013005954A
Authority
MX
Mexico
Prior art keywords
processes
preparation
intermediate compounds
laquinimod sodium
quinoline derivatives
Prior art date
Application number
MX2013005954A
Other languages
English (en)
Inventor
Ehud Marom
Michael Mizhiritskii
Shai Rubnov
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of MX2013005954A publication Critical patent/MX2013005954A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/68—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen
    • C07C63/70—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a procesos para la preparación de derivados de quinolina-3-carboxamida, tal como 5-cloro-3-(etilfenilcarbamoil)-1-metil-2-oxo-1,2-dihidroquinolin- 4-olato de sodio (Laquinimod sódico). La presente invención además se refiere a intermedios formados en dichos procesos.
MX2013005954A 2010-11-28 2011-11-28 Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico. MX2013005954A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41743110P 2010-11-28 2010-11-28
PCT/IL2011/050030 WO2012070051A1 (en) 2010-11-28 2011-11-28 Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium

Publications (1)

Publication Number Publication Date
MX2013005954A true MX2013005954A (es) 2013-07-29

Family

ID=46145452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005954A MX2013005954A (es) 2010-11-28 2011-11-28 Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico.

Country Status (9)

Country Link
US (2) US8865742B2 (es)
EP (1) EP2642855A4 (es)
JP (1) JP2013544819A (es)
CN (1) CN103249306A (es)
AU (1) AU2011333346A1 (es)
CA (1) CA2815935A1 (es)
IN (1) IN2013MN00811A (es)
MX (1) MX2013005954A (es)
WO (1) WO2012070051A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962598B2 (en) 2010-10-14 2015-02-24 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators
WO2012070051A1 (en) 2010-11-28 2012-05-31 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium
US10655779B2 (en) 2011-12-21 2020-05-19 Deka Products Limited Partnership System, method, and apparatus for clamping
EP4153576A4 (en) * 2020-05-21 2024-06-19 StemSynergy Therapeutics, Inc. NOTCH INHIBITORS AND THEIR USES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4633009A (en) 1985-06-18 1986-12-30 Frizsche Dodge & Olcott Inc. Synthesis of methyl N-methylanthranilate
GB2236318A (en) 1989-09-26 1991-04-03 Nitrokemia Ipartelepek Process for preparing pure N-methyl-anthranilic acid methylester
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
JPH07224040A (ja) 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
DE60132702T2 (de) * 2000-08-11 2009-03-19 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
WO2002028818A1 (en) 2000-10-04 2002-04-11 Prom Limited Process for the preparation of alkyl n-alkylanthranilate
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
AU2005324135A1 (en) 2005-01-07 2006-07-13 Arpida Ag Selected benzofuran derivatives
BRPI0617477A2 (pt) * 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
US8552194B2 (en) 2008-04-28 2013-10-08 Actavis Group Ptc Ehf Process for preparing quinoline-3-carboxamide derivatives
EP2318371A2 (en) 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
MX2011002033A (es) 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
WO2012070051A1 (en) 2010-11-28 2012-05-31 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium

Also Published As

Publication number Publication date
US9102592B2 (en) 2015-08-11
US20150051419A1 (en) 2015-02-19
WO2012070051A1 (en) 2012-05-31
CN103249306A (zh) 2013-08-14
EP2642855A4 (en) 2014-05-28
IN2013MN00811A (es) 2015-06-12
JP2013544819A (ja) 2013-12-19
US8865742B2 (en) 2014-10-21
CA2815935A1 (en) 2012-05-31
EP2642855A1 (en) 2013-10-02
US20130245065A1 (en) 2013-09-19
AU2011333346A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
MX353806B (es) Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
UA117122C2 (uk) Хінолонові похідні
MD20150091A2 (ro) Compuşi antivirali
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
NZ743274A (en) Substituted tricyclic compounds as fgfr inhibitors
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
AU2012213775A8 (en) 7-azaindole derivatives
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
PH12013500554A1 (en) Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation
MX2013005954A (es) Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
IN2015DN00085A (es)
WO2012154879A3 (en) Autophagy inhibitors
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2014178064A3 (en) "an improved process for the preparation of fluvoxamine maleate"
MX337610B (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
PH12013502597A1 (en) Pyrazole derivatives useful as aldosterone synthase inhibitors
IL222254A0 (en) 7,11-methanocycloocta [b] quinoline derivatives as highly functionalizable acetylcholinesterase inhibitors
MX2015012350A (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5ht4.
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal